期刊
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
卷 37, 期 6, 页码 783-787出版社
WILEY
DOI: 10.1002/hed.23655
关键词
Rendu-Osler-Weber syndrome; hereditary hemorrhagic telangiectasia (HHT); avastin
资金
- Roche Austria
BackgroundThe purpose of this study was to investigate the efficacy of bevacizumab (Avastin) for the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT). MethodsIn this double blind, placebo controlled trial, 15 adult patients with HHT with a minimum of 2 epistaxis episodes per week were randomized. A history of thromboembolic events or recent or planned surgery led to exclusion. Patients received a single intranasal submucosal injection (10 mL) of 100 mg bevacizumab or placebo. The primary outcome was the relative reduction of average daily epistaxis visual analog score (VAS). ResultsAverage daily posttreatment VAS scores decreased by 27% in the bevacizumab group and by 3% in the placebo group (p = .57). The reduction in HHT epistaxis severity scores was -0.61 greater in the bevacizumab group compared to the placebo group (p = .34). ConclusionResults show a trend toward reduced epistaxis with bevacizumab. This further supports the use of bevacizumab in HHT. Clincial Trials. gov number: NCT01314274 (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 783-787, 2015
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据